Do you want to read an article? Please log in or register.
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients
doi: 10.1093/ibd/izy358.
Inflammatory Bowel Disease
Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials
Clin Gastroenterol Hepatol.
Cheng D, Cushing KC, Cai T, Ananthakrishnan AN
doi: 10.1016/j.cgh.2020.04.070.
Inflammatory Bowel Disease
JAK inhibitors safety in ulcerative colitis: practical implications
J Crohns Colitis.
Agrawal M, Kim ES, Colombel JF
doi: 10.1093/ecco-jcc/jjaa017.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses
United European Gastroenterol J.
Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK
doi: 10.1177/2050640619883566.
RECOMMENDED
Inflammatory Bowel Disease
Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S
doi: 10.1093/ecco-jcc/jjaa027.
Inflammatory Bowel Disease
Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials
Clin Gastroenterol Hepatol.
Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G
doi: 10.1016/j.cgh.2018.11.035.
Inflammatory Bowel Disease
Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study
Aliment Pharmacol Ther.
Adar T, Faleck D, Sasidharan S, Cushing K, Borren NZ, Nalagatla N, Ungaro R, Sy W, Owen SC, Patel A, Cohen BL, Ananthakrishnan AN
doi: 10.1111/apt.15177.
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.